Piper Sandler Upgrades Deciphera (DCPH) to Overweight, 'Vimseltinib, Qinlock Poised for Upside'
Tweet Send to a Friend
(Updated - October 30, 2023 11:44 AM EDT)
Piper Sandler analyst Christopher Raymond upgraded Deciphera (NASDAQ: DCPH) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper Sandler analyst Christopher Raymond upgraded Deciphera (NASDAQ: DCPH) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
